FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1570473746> ?p ?o ?g. }

• W1570473746 abstract "Proceedings: AACR Annual Meeting 2014; April 5-9, 2014; San Diego, CABackground: Anti-CD3 x anti-HER2Bi bispecific antibody (HER2Bi) targeted monoclonal antibody (mAb) activated T cells (ATC) exhibit anti-HER2 cytotoxicity, proliferate, and secrete immunokines upon tumor engagement. This study reports a phase I immunotherapy trial in 9 women with locally advanced breast cancer consisting of infusions of HER2Bi armed ATC (aATC) in combination with interleukin 2 (IL-2) and granulocyte-macrophage-colony stimulating factor (GM-CSF) to evaluate safety, feasibility, time to progression (TTP), overall survival (OS), T cell trafficking, and immune responses. Methods: ATC were produced by stimulating peripheral blood mononuclear cells (PBMC) obtained by leukapheresis with anti-CD3 monoclonal antibody and expanding the ATC in IL-2. ATC were harvested, armed with HER2Bi and cryopreserved in aliqouts. Groups of 3 patients received 20, 40, 80 or 160 x 109 aATC per infusion twice a week for four weeks(Table 1). Results: Eight of 9 patients were ER positive, 2 of 9 were Her 2 overexpressing tumors. The median OS for all patients was 103.5 months (14.3 to 134.7months). Six of 9 patients are alive. Four out of the six patients have no evidence of disease and 2 patients relapsed (one at 77.27 months and the other at 104.67months). It was feasible to grow up to 160 x 109 ATC and both patients assigned to this dose level were able to reach it. There were no cell-based dose limiting toxicities. aATC persisted in the blood for at least a week. aATC infusions induce cellular anti-tumor responses and cytokine responses. Interpretation: Targeting Her2 positive and negative tumors induced cytotoxic anti-tumor responses, increases in Th1 cytokines and IL-12 serum levels, clinical responses that suggest aATC infusions provided a survival benefit. These results are being confirmed in a phase II trial for metastatic breast cancer.View this table:Table 1 Citation Format: Deepa B. Jagtap, Ritesh Rathore, Archana Thakur, Gerald Colvin, Nicola Kouttab, Abby Maizel, Abhinav Deol, Lawrence G. Lum. A phase Ia/Ib trial of chemotherapy followed by infusions of activated T cells armed with OKT3 x trastuzumab bispecific antibody, IL-2 and GM-CSF for stage II/ III, Her2+ or Her2- high risk breast cancer (more than 10+ nodes). [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 2806. doi:10.1158/1538-7445.AM2014-2806" @default.
• W1570473746 created "2016-06-24" @default.
• W1570473746 creator A5021379487 @default.
• W1570473746 creator A5027869313 @default.
• W1570473746 creator A5046786751 @default.
• W1570473746 creator A5047506479 @default.
• W1570473746 creator A5050977698 @default.
• W1570473746 creator A5051092535 @default.
• W1570473746 creator A5079175029 @default.
• W1570473746 creator A5085882360 @default.
• W1570473746 date "2014-09-30" @default.
• W1570473746 modified "2023-09-27" @default.
• W1570473746 title "Abstract 2806: A phase Ia/Ib trial of chemotherapy followed by infusions of activated T cells armed with OKT3 x trastuzumab bispecific antibody, IL-2 and GM-CSF for stage II/ III, Her2+or Her2-high risk breast cancer (more than 10+ nodes)" @default.
• W1570473746 doi "https://doi.org/10.1158/1538-7445.am2014-2806" @default.
• W1570473746 hasPublicationYear "2014" @default.
• W1570473746 type Work @default.
• W1570473746 sameAs 1570473746 @default.
• W1570473746 citedByCount "0" @default.
• W1570473746 crossrefType "proceedings-article" @default.
• W1570473746 hasAuthorship W1570473746A5021379487 @default.
• W1570473746 hasAuthorship W1570473746A5027869313 @default.
• W1570473746 hasAuthorship W1570473746A5046786751 @default.
• W1570473746 hasAuthorship W1570473746A5047506479 @default.
• W1570473746 hasAuthorship W1570473746A5050977698 @default.
• W1570473746 hasAuthorship W1570473746A5051092535 @default.
• W1570473746 hasAuthorship W1570473746A5079175029 @default.
• W1570473746 hasAuthorship W1570473746A5085882360 @default.
• W1570473746 hasConcept C10205521 @default.
• W1570473746 hasConcept C121608353 @default.
• W1570473746 hasConcept C126322002 @default.
• W1570473746 hasConcept C137061746 @default.
• W1570473746 hasConcept C143998085 @default.
• W1570473746 hasConcept C159654299 @default.
• W1570473746 hasConcept C202751555 @default.
• W1570473746 hasConcept C203014093 @default.
• W1570473746 hasConcept C2776694085 @default.
• W1570473746 hasConcept C2777371436 @default.
• W1570473746 hasConcept C2777701055 @default.
• W1570473746 hasConcept C2779786085 @default.
• W1570473746 hasConcept C28328180 @default.
• W1570473746 hasConcept C530470458 @default.
• W1570473746 hasConcept C542903549 @default.
• W1570473746 hasConcept C54355233 @default.
• W1570473746 hasConcept C55493867 @default.
• W1570473746 hasConcept C71924100 @default.
• W1570473746 hasConcept C86803240 @default.
• W1570473746 hasConcept C90924648 @default.
• W1570473746 hasConceptScore W1570473746C10205521 @default.
• W1570473746 hasConceptScore W1570473746C121608353 @default.
• W1570473746 hasConceptScore W1570473746C126322002 @default.
• W1570473746 hasConceptScore W1570473746C137061746 @default.
• W1570473746 hasConceptScore W1570473746C143998085 @default.
• W1570473746 hasConceptScore W1570473746C159654299 @default.
• W1570473746 hasConceptScore W1570473746C202751555 @default.
• W1570473746 hasConceptScore W1570473746C203014093 @default.
• W1570473746 hasConceptScore W1570473746C2776694085 @default.
• W1570473746 hasConceptScore W1570473746C2777371436 @default.
• W1570473746 hasConceptScore W1570473746C2777701055 @default.
• W1570473746 hasConceptScore W1570473746C2779786085 @default.
• W1570473746 hasConceptScore W1570473746C28328180 @default.
• W1570473746 hasConceptScore W1570473746C530470458 @default.
• W1570473746 hasConceptScore W1570473746C542903549 @default.
• W1570473746 hasConceptScore W1570473746C54355233 @default.
• W1570473746 hasConceptScore W1570473746C55493867 @default.
• W1570473746 hasConceptScore W1570473746C71924100 @default.
• W1570473746 hasConceptScore W1570473746C86803240 @default.
• W1570473746 hasConceptScore W1570473746C90924648 @default.
• W1570473746 hasLocation W15704737461 @default.
• W1570473746 hasOpenAccess W1570473746 @default.
• W1570473746 hasPrimaryLocation W15704737461 @default.
• W1570473746 hasRelatedWork W1875869773 @default.
• W1570473746 hasRelatedWork W2010941192 @default.
• W1570473746 hasRelatedWork W2011944525 @default.
• W1570473746 hasRelatedWork W2060974366 @default.
• W1570473746 hasRelatedWork W2285025842 @default.
• W1570473746 hasRelatedWork W2483562035 @default.
• W1570473746 hasRelatedWork W2490293660 @default.
• W1570473746 hasRelatedWork W2499805877 @default.
• W1570473746 hasRelatedWork W2553329096 @default.
• W1570473746 hasRelatedWork W2559217065 @default.
• W1570473746 hasRelatedWork W2590648077 @default.
• W1570473746 hasRelatedWork W2591273445 @default.
• W1570473746 hasRelatedWork W2592152276 @default.
• W1570473746 hasRelatedWork W2789422517 @default.
• W1570473746 hasRelatedWork W3013356138 @default.
• W1570473746 hasRelatedWork W3033329685 @default.
• W1570473746 hasRelatedWork W3034651999 @default.
• W1570473746 hasRelatedWork W3177687441 @default.
• W1570473746 hasRelatedWork W3182143239 @default.
• W1570473746 hasRelatedWork W870358426 @default.
• W1570473746 isParatext "false" @default.
• W1570473746 isRetracted "false" @default.
• W1570473746 magId "1570473746" @default.
• W1570473746 workType "article" @default.